Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer

Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of... ORIGINAL ARTICLE Combination Treatment with All-Trans Retinoic Acid  Prevents Cisplatin-Induced Enrichment of CD133 Tumor-Initiating Cells and Reveals Heterogeneity of  Cancer Stem Cell Compartment in Lung Cancer Massimo Moro, MSc,* Giulia Bertolini, PhD,* Ugo Pastorino, MD,† Luca Roz,* and Gabriella Sozzi, PhD* counteracting cisplatin resistance of CD133 cells, reducing both Abstract: The existence of specific cellular subpopulations within local tumor growth and dissemination. In addition, our approach primary tumors with increased tumorigenic potential and chemother- discloses a further level of complexity of chemotherapy-resistant apy resistance (tumor initiating cells, TICs) holds great therapeutic CD133 TICs, revealing phenotypical and functional heterogeneity implications. Resistant cells can remain quiescent for long periods of the cancer stem cell compartment in lung cancer. and be responsible for local relapses and metastasis. We and others have previously described in non–small-cell lung cancer the presence Key Words: Non–small-cell lung cancer, Retinoic acid, Cancer stem of cisplatin-resistant CD133 cells with tumor-initiating potential and cells dynamics, Cisplatin resistance. co-expression of CXCR4 as possible indicator of TICs with dissemi- (J Thorac Oncol. 2015;XX: 00–00) nating potential. In this study, we report, by in vitro cell fate tracing systems, heterogeneity within the TIC compartment with a highly quiescent pool and a slowly dividing subpopulation, both contain- on–small-cell lung cancer (NSCLC), representing approx- + + - ing CD133 cells but respectively enriched for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer

Download PDF
10 pages

Loading next page...
 
/lp/wolters-kluwer-health/combination-treatment-with-all-trans-retinoic-acid-prevents-cisplatin-ynL2fQeYwL
Copyright
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000563
pmid
26020124
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Combination Treatment with All-Trans Retinoic Acid  Prevents Cisplatin-Induced Enrichment of CD133 Tumor-Initiating Cells and Reveals Heterogeneity of  Cancer Stem Cell Compartment in Lung Cancer Massimo Moro, MSc,* Giulia Bertolini, PhD,* Ugo Pastorino, MD,† Luca Roz,* and Gabriella Sozzi, PhD* counteracting cisplatin resistance of CD133 cells, reducing both Abstract: The existence of specific cellular subpopulations within local tumor growth and dissemination. In addition, our approach primary tumors with increased tumorigenic potential and chemother- discloses a further level of complexity of chemotherapy-resistant apy resistance (tumor initiating cells, TICs) holds great therapeutic CD133 TICs, revealing phenotypical and functional heterogeneity implications. Resistant cells can remain quiescent for long periods of the cancer stem cell compartment in lung cancer. and be responsible for local relapses and metastasis. We and others have previously described in non–small-cell lung cancer the presence Key Words: Non–small-cell lung cancer, Retinoic acid, Cancer stem of cisplatin-resistant CD133 cells with tumor-initiating potential and cells dynamics, Cisplatin resistance. co-expression of CXCR4 as possible indicator of TICs with dissemi- (J Thorac Oncol. 2015;XX: 00–00) nating potential. In this study, we report, by in vitro cell fate tracing systems, heterogeneity within the TIC compartment with a highly quiescent pool and a slowly dividing subpopulation, both contain- on–small-cell lung cancer (NSCLC), representing approx- + + - ing CD133 cells but respectively enriched for

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: May 1, 2015

There are no references for this article.